�°������ϲ���Ļ��Ϣ

Researchers at �°������ϲ���Ļ��Ϣ Davis are developing a new type of pain medication from an unusual source — tarantula venom.

The project is part of the , aimed at ending opioid addiction and creating non-addictive therapies to treat pain.

Vladimir Yarov-Yarovoy, a professor of physiology and membrane biology, and Heike Wulff, a professor of pharmacology, are leading the 20-person team using computational biology to turn a poisonous peptide into one that can relieve pain.  are smaller versions of proteins.

Evolutionary head start

“Spiders and scorpions have millions of years of evolution optimizing peptide, protein and small-molecule poisons in their venom, which we can take advantage of,” said Bruce Hammock, a �°������ϲ���Ļ��Ϣ Davis distinguished professor who is working on the new pain reliever. “The same venoms that can cause pain and neurological dysfunction can also help nerves work better and reduce pain.”

Approximately  of adults in the U.S., around 50 million, are affected by chronic pain. About 11 million are affected by , defined as pain that lasts three months or longer and restricts a significant activity, like being unable to work outside the home, go to school or do household chores.

A few nonopioid medications are available to help those with chronic pain, and  can help. In general, though, people with chronic pain have limited options for pain relief. 

PAIN RELIEF INNOVATTION AT �°������ϲ���Ļ��Ϣ DAVIS

A new pain reliever from tarantula venom isn’t the only non-narcotic drug being developed at �°������ϲ���Ļ��Ϣ Davis. In 2020, the Food and Drug Administration granted fast-track designation to a non-narcotic drug candidate from , a pharmaceutical company founded by �°������ϲ���Ļ��Ϣ Davis Distinguished Professor Bruce Hammock to treat chronic pain in humans and companion animals. Hammock holds a joint appointment with the �°������ϲ���Ļ��Ϣ Davis Department of Entomology and Nematology and the �°������ϲ���Ļ��Ϣ Davis Comprehensive Cancer Center. The drug candidate, known as EC5026, targets a novel pathway to block the underlying cause of certain types of pain. 

 

“For strong pain, drugs like ibuprofen or aspirin are just not strong enough. Opioids are strong enough, but they have the problem of tolerance development and addiction,” said Wulff.

Opioid addiction and misuse in the United States surged in recent years, leading to a significant health crisis. In 2019, nearly 50,000 people in the United States .

“What we need are new medications, new therapies with improved risk profiles,” said David Copenhaver, a member of the team and director of Cancer Pain Management and Supportive Care at �°������ϲ���Ļ��Ϣ Davis Health. “There’s been a push to develop other, better, safer, less addictive — or zero addictive — medication and therapeutics for pain management,” said Copenhaver, who is also the associate director for the  at �°������ϲ���Ļ��Ϣ Davis.

Protein ‘channels’

To create a nonaddictive but strong pain medication, the researchers are focused on pain signals traveling on sensory neurons. To stop these signals, they have targeted a particular type of protein “channel” found on the cell membranes of neurons and muscles.

These channels, called voltage-gated sodium channels, play a crucial role in generating signals to nerves and muscles.

Nine different types of these channels have been identified in humans. The sodium symbol is Na, so the voltage-gated channels are referred to as Nav1.1 through Nav1.9.

The Nav1.7 channel is the one that interests pain scientists the most because it is a key source of pain transmission.

Upside, downside

That’s where the tarantula venom comes in. A peptide found in the venom of the Peruvian green velvet tarantula blocks Nav1.7, preventing it from transmitting signals, including those for pain.

“The promise of a Nav1.7 inhibitor is that we would have something that is as effective as an opioid, but not addictive,” said Wulff, who specializes in preclinical therapeutics development targeting ion channels.

The challenge with the protein in the tarantula venom is that it doesn’t just block Nav1.7 channels in the sensory nerves. In its natural form, the peptide blocks all Nav1.7 channels, including those in the muscles and the brain, meaning that it could cause terrible side effects.

Redesigning a peptide

To solve this problem, the researchers are using an approach known as “toxineering.” They are trying to engineer — modify — the toxin in the venom to block pain signals but not create unwanted side effects.

To do this, they are using a computer program developed by the University of Washington called . The complex modeling software lets the team create many different iterations of the tarantula peptide, which they can then synthesize and test in the lab.

“Using the Rosetta software, we can take a natural peptide and then redesign it and make it into a therapeutic,” said Yarov-Yarovoy, an expert in computational structural modeling of peptide toxins. “Our lead peptides already show efficacy at the level of morphine, but without the side effects of opioids.”

Their preliminary results are extremely promising, but a lot of work remains to be done. The potential therapeutic candidates will need to be tested in animals, and if found safe, carefully tested in humans. The researchers estimate any new medication is at least five years away.

‘A real chance’

“What Vladimir has put together is really fantastic because no one scientist could have any hope of tackling a project that is this hard,” Hammock said about the 20-person team. “But having a collection of people makes it fun and exciting, and I think it gives us a real chance at relieving pain.”

Additional team members include Karen Wagner, Jon T. Sack, Theanne Griffith, Scott Fishmann, Hai Nguyen, Daniel J. Tancredi, Nieng Yan, William Schmidt, Andre Ghetti, Neil Castle, Michael Pennington, Phuong Tran Nguyen, Brandon Harris, Diego Lopez Mateos, Robert Stewart and Parashar Thapa.

The tarantula venom research at �°������ϲ���Ļ��Ϣ Davis is funded by a $1.5 million grant from . FOA Number: .